Business
Hemato-Oncology Expert, Dr. Sigal Tavor (MD) Joins Cannabics Pharmaceuticals' Board of Advisors
Hemato-Oncology Expert, Dr. Sigal Tavor (MD) Joins Cannabics Pharmaceuticals' Board of Advisors.
About this update from Cnbx Pharmaceuticals Inc.
[{"type":"text","content":"\n\n\n\nHemato-Oncology Expert, Dr. Sigal Tavor (MD) Joins Cannabics Pharmaceuticals' Board of Advisors\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nHemato-Oncology Expert, Dr. Sigal Tavor (MD) Joins Cannabics Pharmaceuticals' Board of Advisors\nPR Newswire\nTEL AVIV, Israel and BETHESDA, Md., Aug. 23, 2021\n\n\n\nTEL AVIV, Israel and BETHESDA, Md., Aug. 23, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced today that Dr. Sigal Tavor (MD), a renowned Hemato-Oncology expert, has joined the company's Board of Advisors. \n\n \n \n \n \n \n \n\n \nThe announcement follows the company's recent expansion of its Board of Advisors to include Prof. Caroline Robert (MD, Ph.D.), a Melanoma expert along with Prof. Amos Toren (MD), Prof. Zamir Halpern (MD), Dr. Erez Scapa (MD), Dr. Dana Ben-Ami Shor (MD), Dr. Sigalit Arieli-Portnoy (Ph.D.) and Dr. Tal Mofkadi (Ph.D.). The announcement is made also as the company expands its Board of Directors, having been joined by Dr. Inbar Maymon-Pomeranchik (Ph.D.), and Dr. Gil Feiler (Ph.D.) as Independent Directors.\nThe nomination of Dr. Tavor is part of the company's strategy to include specialists in a variety of specific cancers and enhance the company's Drug Discovery Platform and other research capabilities to focus on Hematology in addition to the other cancer programs currently already under way. Accordingly, the company plans to continue down the clinical path for the existing drug candidate projects and continue producing new drug candidates for additional indications. \nDr. Gil Feiler, Director and Advisory Board Chair commented: \"It gives me great pleasure to welcome Dr. Tavor onto our Board of Advisors. Dr. Tavor is an exceptional clinician and researcher that has dedicated her professional life to improve patient care. Dr. Tavor brings a wealth of experience in Hematology which will surely translate into invaluable input for the company.\"\nAbout Dr. Sigal Tavor:\nDr. Tavor currently serves as a S...